Conference Coverage
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
The Future of MRD in Breast Cancer Treatment
Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma
Ropeginterferon Alfa-2b Yields Durable Responses in Essential Thrombocythemia
How MRD Is Being Used to Guide Treatment Decisions
FDA Approval of SC Daratumumab: A Turning Point in High-Risk SMM
Latest News
Shorts
Podcasts
Experts Delve Into Organ Preservation for Genitourinary Cancers
Benjamin Garmezy, MD, and Alexander Kenigsberg, MD, discuss strategies for preserving organs in GU cancers in the Treating Together podcast.
Navigating Modern Lung Cancer Treatment and Clinical Trial Access
Edward S. Kim, MD, MBA, and Neel Shah, MD, discuss advancing lung cancer care and tackling real-world access barriers for community physicians in the Treating Together podcast.
Advancing Prostate Cancer Treatment With Shared Decision-Making
In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.
Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning
Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.
BMT CTN 1902 in Myeloma: Key Findings With Garfall
In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
Exploring Innovations in Lymphoma Treatment With Russler-Germain
David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.
Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.
Juneja Explores AI’s Impact in Early Cancer Detection and Treatment
In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.
How AI Is Revolutionizing Oncology in Diagnosis, Treatment, and Research
In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, discusses the transformative impact of artificial intelligence in oncology.
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Videos
Treating Together
Treating MDS
Precise Management of EGFR Exon 20-Positive Non–Small Cell Lung Cancer
For EGFR-positive disease with exon 20 insertions, methods used to treat the wide EGFR-positive population are not successful for these patients, calling for more targeted therapies.
All News
During a live event, Yelena Y. Janjigian, MD, moderated a discussion on which frontline treatment to give a 60-year-old patient with stage IV gastric adenocarcinoma.
FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient outcomes in early intervention.
Lifileucel shows sustained efficacy and safety in advanced melanoma, highlighting its potential as a key treatment for ICI-resistant cases.
Sonrotoclax gains FDA priority review for relapsed mantle cell lymphoma, showcasing promising efficacy and safety in challenging patient populations.
A new subcutaneous formulation of toripalimab shows comparable efficacy to the intravenous version, enhancing convenience for lung cancer patients.
FDA approves durvalumab with FLOT chemotherapy for early-stage gastric cancer, showing promising survival rates in recent clinical trials.
AVZO-103 receives FDA fast track designation, offering hope for advanced urothelial cancer patients previously treated with enfortumab vedotin.
A phase 2 study reveals high efficacy and manageable safety of venetoclax plus obinutuzumab for untreated CLL/SLL in Japanese patients.
FDA designates NBM-BMX as an orphan drug for metastatic uveal melanoma, highlighting its potential in treating this aggressive cancer.
The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and increases treatment-related risks.
Selinexor-based therapies enhance T-cell activation in multiple myeloma patients, revealing potential strategies for improving treatment efficacy and overcoming resistance.
Dr Benjamin George champions patient-centered oncology in rural Nebraska, enhancing local cancer care access and fostering community support for patients.
Recent polling shows oncologists changing inclination in treatment for mHSPC based on tolerability profiles.
A study reveals a U-shaped relationship between BMI and CAR T-cell therapy outcomes in multiple myeloma, highlighting the need for further research.
During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.
A recent study reveals cognitive behavioral therapy significantly enhances lung cancer patients' ability to manage dyspnea and anxiety, improving overall quality of life.
Isatuximab shows promising efficacy and safety for relapsed AL amyloidosis, achieving high response rates and favorable survival outcomes in a phase 2 trial.
The IGNYTE trial reveals that RP1 combined with nivolumab offers significant, durable responses in advanced melanoma patients previously resistant to anti-PD-1 therapy.
New findings reveal that GDF-15 neutralization with visugromab and nivolumab significantly enhances long-term responses in advanced cancer patients.
Discover the latest advancements in oncology, including groundbreaking treatments for breast cancer, gastroesophageal cancer, and neurofibromatosis.
Recent research reveals that GLP-1 receptor agonists significantly lower 5-year mortality rates in colon cancer patients, highlighting their potential in cancer treatment.
Patients with non-muscle invasive bladder cancer seek improved communication with providers about treatment options, highlighting a need for collaborative care discussions.
Explore the evolving role of medical oncologists in treating non–muscle invasive bladder cancer with innovative immunotherapy options and trial insights.
Eflornithine combined with lomustine shows promising survival benefits for patients with recurrent IDH-mutant grade 3 astrocytoma in recent trials.
The FDA approves enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, significantly improving survival rates post-surgery.
Zipalertinib shows promise as a treatment for advanced NSCLC with EGFR mutations, demonstrating significant response rates in recent trials.
The JULIET trial reveals long-term efficacy and safety of CAR-T therapy tisagenlecleucel in relapsed/refractory large B-cell lymphoma patients.
A clinical study reveals that combining third-generation tyrosine kinase inhibitors with azacitidine effectively treats chronic myeloid leukemia, showing promising patient outcomes.
High LAG3 expression in metastatic renal cell carcinoma enhances initial immunotherapy response but does not improve long-term survival outcomes.
During a live event, Hannah Choe, MD, discussed options for steroid-resistant cGVHD based on organ involvement, efficacy, and safety profiles.
Physicians at VCU's Massey Comprehensive Cancer Center explored their experiences using tumor-infiltrating lymphocytes to treat patients with advanced melanoma.
The FDA approves new denosumab biosimilars, expanding treatment options for osteoporosis and cancer-related bone issues, enhancing patient access to care.
The FDA reviews zidesamtinib for advanced ROS1+ NSCLC, promising new treatment options for patients resistant to current therapies.
